Pulmonary Mucormycosis Treated Successfully with Posaconazole as Salvage Therapy.
- Author:
Jiwon CHOI
1
;
Yeun Seoung CHOI
;
Myoung Kyu LEE
;
Sang Ha KIM
;
Suk Joong YONG
;
Kye Chul SHIN
;
Seok Jeong LEE
;
Ye Ryung JUNG
;
Won Yeon LEE
Author Information
1. Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. wonylee@yonsei.ac.kr
- Publication Type:Case Report
- Keywords:
Mucormycosis;
Posaconazole;
Salvage therapy
- MeSH:
Antifungal Agents;
Early Diagnosis;
Humans;
Immunity, Innate;
Mortality;
Mucorales;
Mucormycosis*;
Prognosis;
Salvage Therapy*
- From:Keimyung Medical Journal
2015;34(2):127-132
- CountryRepublic of Korea
- Language:English
-
Abstract:
Mucormycosis (formerly known as zygomycosis) is a life-threatening opportunistic mycosis that infects a broad range of hosts with qualitative or quantitative defects in innate immunity. The overall mortality rate of pulmonary mucormycosis is above 70%. The prognosis and outcome of pulmonary mucormycosis have not improved significantly over the last decade, mainly because of difficulty in early diagnosis and the limited activity of current antifungal agents against members of the order Mucorales. We report a case of pulmonary mucormycosis treated successfully with posaconazole as salvage therapy. We suggest that posaconazole may be considered as an alternative therapeutic approach in patients with invasive pulmonary mucormycosis who are unable to tolerate surgical treatment.
